Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.89 |
| ▸ | HPGD | P15428 | 4/20 | 0.89 |
| ▸ | LMNA | P02545 | 4/20 | 0.89 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.89 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.89 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.89 |
| ▸ | CASP1 | P29466 | 3/20 | 0.89 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.89 |
| ▸ | MAPT | P10636 | 3/20 | 0.89 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.89 |
| ▸ | CASP7 | P55210 | 2/20 | 0.89 |
| ▸ | MEN1 | O00255 | 2/20 | 0.89 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.89 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.85 |
| ▸ | UBE2N | P61088 | 1/20 | 0.76 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.76 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.60 |
| ▸ | GHSR | Q92847 | 5/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6081481 | 0.78 | GHSR (0.76) | TSHRHPGDLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL7058846 | 0.74 | TSHR (0.72) | TSHRHPGDLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL29608448 | 0.73 | PTGS2 (0.61) | TSHRHPGDLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL18046665 | 0.73 | PTGS2 (0.61) | TSHRHPGDLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL12204291 | 0.73 | LMNA (1.00) | TSHRHPGDLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL18046667 | 0.73 | PTGS2 (0.61) | TSHRHPGDLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL1225498 | 0.72 | PTGS2 (0.67) | TSHRHPGDLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL3638285 | 0.71 | GHSR (1.00) | KMT2AMEN1PTGS2GHSR | |
| SCHEMBL29058683 | 0.71 | ALDH1A1 (0.82) | TSHRHPGDLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL1224417 | 0.71 | ALDH1A1 (0.77) | TSHRHPGDLMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9566284-B2 | Agents and methods for treating ischemic and other diseases | NONO INC. (CA) | 2017-02-14 | — | — | US | disclosed |
| US-9566284-B2 | Agents and methods for treating ischemic and other diseases | NONO INC. (CA) | 2017-02-14 | — | — | US | disclosed |
| US-9334256-B2 | Agents and methods for treating ischemic and other diseases | NONO INC. (CA) | 2016-05-10 | — | — | US | disclosed |
| US-20140235619-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO INC. (CA) | 2014-08-21 | — | — | US | disclosed |
| US-20140235619-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO INC. (CA) | 2014-08-21 | — | — | US | disclosed |
| US-20140221423-A1 | Agents And Methods For Treating Ischemic And Other Diseases | NONO INC. (CA) | 2014-08-07 | — | — | US | disclosed |
| US-20140221423-A1 | Agents And Methods For Treating Ischemic And Other Diseases | NONO INC. (CA) | 2014-08-07 | — | — | US | disclosed |
| US-20110251182-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO, INC. (CA) | 2011-10-13 | — | — | US | disclosed |
| US-20110251182-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO, INC. (CA) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251182-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | TRPM7, TRPM8, TRPM6 | TSHR 2920/4885HPGD 768/4885LMNA 1163/4885 |
| US-20140235619-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | TRPM7, TRPM8, TRPM6 | TSHR 2920/4885HPGD 768/4885LMNA 1163/4885 |
| US-20140221423-A1 | Agents And Methods For Treating Ischemic And Other Diseases | TRPM7, TRPM8, TRPM5 | TSHR 3682/4885HPGD 262/4885LMNA 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.